Research Paper Volume 11, Issue 11 pp 3523—3535
Biological markers and cardiac remodelling following the myocardial infarction
- 1 Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russian Federation
- 2 State Budget Educational Institution Higher Professional Education, Siberian State Medical University, Russian Ministry of Health and Social Care Development, Tomsk 634050, Russian Federation
accepted: May 22, 2019 ; received: January 21, 2019 ; published: June 10, 2019 ;https://doi.org/10.18632/aging.101994
How to Cite
Copyright: Gruzdeva et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: To assess growth stimulating factor ST2 and N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in the sera of myocardial infraction (MI) patients, and their correlation with the adaptive and maladaptive variants of cardiac remodelling.
Methods: 87 patients (65 male, 22 females; 67±8.36 years) with ST-elevated MI were included in this study, and 67 patients had an adaptive, physiological, while 20 patients had a maladaptive, pathological variant of myocardium remodelling.
Results: On day 1, ST2 and NT-proBNP levels were shown to increase 2.4 and 4.5 folds, respectively, compared with those in the control. ST2 levels in patients with maladaptive remodelling were 1.5-fold higher than those in the adaptive remodelling group. On day 12, a decrease in ST2 levels was observed in both groups. NT-proBNP levels increased 1.8 folds in both groups on day 1, compared with those in the controls. Increased ST2 levels on day 1 after MI were shown to increase the risk of maladaptive remodelling 4.5 folds, while high NT-proBNP levels increased this risk 2.3 times.
Conclusions: ST2 level determination allows us to predict the risk of maladaptive remodelling with a higher sensitivity and specificity than using NT-proBNP levels.
ST2: growth stimulating factor; LV: left ventricle; NT-proBNP: N-terminal pro b-type natriuretic peptide; AH: arterial hypertension; PCI: percutaneous coronary intervention; ECG: electrocardiographic; EF: ejection fraction; LA: left atrial; EDD: end-diastolic dimension; ESV: end-systolic volume; IVS: interventricular septum; LVPW: LV posterior wall dimension; CAD: coronary artery disease.